Welcome to our dedicated page for Agilent Technologies news (Ticker: A), a resource for investors and traders seeking the latest updates and insights on Agilent Technologies stock.
Agilent Technologies Inc. reports developments across analytical and clinical laboratory technologies, including instruments, software, services and scientific expertise used by life science, diagnostics, applied, biopharmaceutical, chemical, advanced materials, clinical lab, environmental, food, forensics, academic and government customers. Company updates commonly address financial results, product launches, laboratory workflows and changes in senior legal, governance and compliance leadership.
Recent Agilent news has highlighted the BioTek Cytation 9 cell imaging multimode reader for cell-based research and high-content screening, cancer research and diagnostics workflows, and FDA-approved companion diagnostic indications for PD-L1 IHC 22C3 pharmDx, including use in identifying certain esophageal or gastroesophageal junction carcinoma patients who may be eligible for KEYTRUDA.
TORM plc (NASDAQ: TRMD / TRMD A) increased its share capital by 106,468 A-shares following exercise of Restricted Share Units (RSUs), corresponding to a nominal value of USD 1,064.68. A total of 34,880 shares were subscribed at DKK 131.80 and 71,588 at DKK 148.70.
The new ordinary A-shares carry voting and dividend rights as of issuance, are negotiable instruments, and are expected to be listed on Nasdaq Copenhagen as soon as possible. Transfer restrictions may apply in some jurisdictions, including U.S. securities law. After the increase, share capital totals USD 1,019,306.41 divided into 101,930,641 A-shares.
Agilent (NYSE: A) launched Agilent Advanced Therapeutics, a unified CDMO solution integrating BIOVECTRA (Canada) and Nucleic Acid Solutions (Colorado) to provide end-to-end development and manufacturing across discovery, process development, and clinical- and commercial-scale production.
The CDMO portfolio includes oligonucleotides, microbial fermentation, complex and synthetic chemistry, bioreagents, highly potent APIs, and cell line development, intended to streamline customer access to scalable, customizable manufacturing under a single partner.
TORM plc (NASDAQ: TRMD, TRMD A) announced on March 9, 2026 that Oaktree Capital Group Holdings GP, LLC notified the company that OCM Njord Holdings S.à r.l. holds 23,839,575 shares, representing 23.39% of TORM's total share capital and voting rights.
The disclosure was made under section 30 of the Danish Capital Markets Act and names the investor and the exact stake size.
Agilent (NYSE: A) has agreed to acquire Biocare Medical for $950 million in an all-cash transaction, adding a complementary portfolio of IHC, ISH and FISH antibodies, reagents and instruments.
Biocare generated over $90 million revenue in 2025, posted annual double-digit revenue and profit growth since 2021, and the deal is expected to be accretive to Agilent’s top-line growth, margin profile and non-instrument revenue mix in Year 1, with EPS accretion ~12 months after close. Closing is subject to regulatory approvals and expected by Agilent’s Q4 FY2026.
TORM plc (A) has issued formal notice and full proposals for its Annual General Meeting to be held at noon London time on Wednesday, 15 April 2026. The notice details the business to be proposed at the AGM and provides investor contact names and phone numbers for queries.
TORM plc (Nasdaq: A) has adopted a long-term incentive program granting Restricted Share Units (RSUs) to employees and Executive Director Jacob Meldgaard. For 2025, 1,356,087 RSUs will be granted and 255,200 RSUs to Jacob Meldgaard, vesting over three years from 01 January 2027.
Each RSU may be exercised for one TORM A-share at an exercise price of DKK 167.14; theoretical market value of the allocation is USD 10.9m. P&L impact is forecast at USD 6.2m (2026), 3.3m (2027) and 1.4m (2028).
TORM (A) reported full-year 2025 results with TCE USD 910m, adjusted EBITDA USD 578m and net profit USD 286m. Return on invested capital fell to 11.5% from 24.3% in 2024. The Board approved a Q4 dividend of USD 0.70 per share payable 25 March 2026. For 2026 TORM expects TCE USD 850–1,250m and EBITDA USD 500–900m, with 23% of 2026 earning days covered as of 17 February 2026.
Fleet activity included nine second-hand acquisitions, purchase options exercised on 14 leaseback vessels, and a year-end fleet of 93 vessels.
Agilent (NYSE: A) reported Q1 FY2026 revenue of $1.80 billion, up 7.0% reported and 4.4% core year-over-year, with GAAP EPS of $1.07 and non-GAAP EPS of $1.36. The company raised FY26 revenue guidance to $7.3–$7.5 billion and increased non-GAAP EPS range to $5.90–$6.04.
Segments: LDG revenue $679M (16.0% margin), ACG $758M (31.6% margin), AMG $361M (25.8% margin). Q2 revenue guide is $1.79–$1.82 billion; Q2 non-GAAP EPS $1.39–$1.42. Management cited weather headwinds but reaffirmed core growth and margin expansion.
Agilent (NYSE: A) will participate in TD Cowen’s 46th Annual Health Care Conference with a fireside chat featuring CFO Adam Elinoff and Head of Investor Relations Tejas Savant on March 3, 2026, 11:10–11:40 a.m. EST in Boston.
A live audio webcast and replay will be available on Agilent’s Investor Relations website. Agilent reported $6.95 billion revenue for fiscal 2025 and employs approximately 18,000 people worldwide.
Agilent (NYSE: A) announced a quarterly cash dividend of 25.5 cents per share, payable April 22, 2026, to shareholders of record at the close of business March 31, 2026. The company said future dividend timing and amounts remain subject to board determination.
Financials: Agilent reported $6.95 billion revenue in fiscal 2025 and employs approximately 18,000 people worldwide.